- Home
- MMD vs CTNM Comparison
MMD vs CTNM Comparison
Compare MMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMD
- CTNM
- Stock Information
- Founded
- MMD 2012
- CTNM 2009
- Country
- MMD United States
- CTNM United States
- Employees
- MMD N/A
- CTNM N/A
- Industry
- MMD Investment Managers
- CTNM
- Sector
- MMD Finance
- CTNM
- Exchange
- MMD Nasdaq
- CTNM Nasdaq
- Market Cap
- MMD 274.9M
- CTNM 248.7M
- IPO Year
- MMD N/A
- CTNM 2024
- Fundamental
- Price
- MMD $14.55
- CTNM $9.94
- Analyst Decision
- MMD
- CTNM Strong Buy
- Analyst Count
- MMD 0
- CTNM 4
- Target Price
- MMD N/A
- CTNM $22.75
- AVG Volume (30 Days)
- MMD 74.7K
- CTNM 206.5K
- Earning Date
- MMD 01-01-0001
- CTNM 08-05-2025
- Dividend Yield
- MMD 4.88%
- CTNM N/A
- EPS Growth
- MMD N/A
- CTNM N/A
- EPS
- MMD N/A
- CTNM N/A
- Revenue
- MMD N/A
- CTNM N/A
- Revenue This Year
- MMD N/A
- CTNM N/A
- Revenue Next Year
- MMD N/A
- CTNM N/A
- P/E Ratio
- MMD N/A
- CTNM N/A
- Revenue Growth
- MMD N/A
- CTNM N/A
- 52 Week Low
- MMD $14.30
- CTNM $3.35
- 52 Week High
- MMD $17.67
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- MMD 44.12
- CTNM 79.45
- Support Level
- MMD $14.40
- CTNM $6.56
- Resistance Level
- MMD $14.62
- CTNM $6.95
- Average True Range (ATR)
- MMD 0.26
- CTNM 0.82
- MACD
- MMD -0.02
- CTNM 0.31
- Stochastic Oscillator
- MMD 12.50
- CTNM 85.28
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.